MCID: ATN004
MIFTS: 44

Autonomic Neuropathy

Categories: Neuronal diseases

Aliases & Classifications for Autonomic Neuropathy

MalaCards integrated aliases for Autonomic Neuropathy:

Name: Autonomic Neuropathy 12 54 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:11504
NCIt 49 C27033
UMLS 71 C0259749

Summaries for Autonomic Neuropathy

MalaCards based summary : Autonomic Neuropathy is related to hereditary sensory and autonomic neuropathy type 1 and neuropathy, hereditary sensory and autonomic, type ia. An important gene associated with Autonomic Neuropathy is RETREG1 (Reticulophagy Regulator 1), and among its related pathways/superpathways are Neuroscience and FOXA2 and FOXA3 transcription factor networks. The drugs Quinapril and Vildagliptin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and kidney, and related phenotypes are homeostasis/metabolism and behavior/neurological

Wikipedia : 74 Autonomic neuropathy (AN or AAN) is a form of polyneuropathy that affects the non-voluntary, non-sensory... more...

Related Diseases for Autonomic Neuropathy

Diseases related to Autonomic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 483)
# Related Disease Score Top Affiliating Genes
1 hereditary sensory and autonomic neuropathy type 1 34.9 SPTLC2 SPTLC1 RETREG1
2 neuropathy, hereditary sensory and autonomic, type ia 34.2 WNK1 SPTLC2 SPTLC1
3 neuropathy, hereditary sensory and autonomic, type iib 34.1 WNK1 SCN9A RETREG1 KIF1A
4 neuropathy, hereditary sensory and autonomic, type ic 34.1 SPTLC2 SPTLC1
5 neuropathy, hereditary sensory and autonomic, type iii 34.0 SPTLC1 NTRK1 NGF ELP1
6 neuropathy, hereditary sensory and autonomic, type v 33.8 WNK1 SPTLC1 RETREG1 NTRK1 NGF KIF1A
7 neuropathy, hereditary sensory and autonomic, type i, with cough and gastroesophageal reflux 33.8 SPTLC2 SPTLC1
8 neuropathy, hereditary sensory and autonomic, type viii 33.8 SCN11A RETREG1 NTRK1 NGF
9 diabetic autonomic neuropathy 33.5 NGF MLN INS GAST EPO AKR1B1
10 neuropathy, hereditary sensory and autonomic, type iia 33.4 WNK1 SPTLC2 SPTLC1 SCN9A RETREG1 NTRK1
11 hereditary sensory neuropathy 33.2 WNK1 SPTLC2 SPTLC1 SCN9A RETREG1 NTRK1
12 autonomic dysfunction 33.0 SPTLC2 SPTLC1 SCN9A RETREG1
13 indifference to pain, congenital, autosomal recessive 33.0 SCN9A SCN11A
14 sensory peripheral neuropathy 32.3 SPTLC1 RETREG1 NTRK1 NGF ALB AKR1B1
15 diabetic neuropathy 32.3 SCN9A NTRK1 NGF INS EPO AKR1B1
16 neuropathy 31.2 WNK1 SPTLC2 SPTLC1 SCN9A SCN11A RETREG1
17 gastroparesis 31.1 MLN GAST CCK
18 microvascular complications of diabetes 3 31.0 INS ALB AKR1B1
19 osteomyelitis 30.9 SPTLC2 SPTLC1 RETREG1
20 diabetic polyneuropathy 30.9 NGF INS AKR1B1
21 microvascular complications of diabetes 1 30.7 NGF INS AKR1B1
22 acroosteolysis 30.6 RETREG1 ALB
23 autonomic nervous system disease 30.5 TTR SCN9A NPY NGF INS ALB
24 hyperglycemia 30.4 INS CCK ALB AKR1B1
25 sleep apnea 30.4 INS EPO ALB
26 uremia 30.4 INS EPO ALB
27 constipation 30.3 NPY MLN GAST CCK AKR1B1
28 background diabetic retinopathy 30.2 INS ALB AKR1B1
29 algoneurodystrophy 30.2 NGF INS
30 peripheral vascular disease 30.1 SCN9A INS GAST EPO ALB
31 irritable bowel syndrome 30.1 NGF MLN CCK
32 neurogenic arthropathy 30.0 SPTLC1 SCN9A NGF INS
33 congestive heart failure 30.0 NPY INS EPO ALB
34 diabetes mellitus 30.0 NPY MLN INS EPO CCK ALB
35 polyneuropathy 29.9 TTR NGF INS EPO ALB AKR1B1
36 ileus 29.8 MLN INS CCK
37 gallbladder disease 29.8 MLN INS CCK ALB
38 diarrhea 29.7 TTR MLN GAST CCK ALB
39 hyperparathyroidism 29.7 GAST EPO ALB
40 duodenitis 29.7 INS GAST CCK ALB
41 duodenal ulcer 29.7 MLN INS GAST CCK
42 cholelithiasis 29.6 INS GAST CCK ALB
43 demyelinating polyneuropathy 29.6 TTR NGF ALB
44 charcot-marie-tooth disease 29.6 WNK1 SPTLC2 SPTLC1 SCN9A SCN11A RETREG1
45 celiac disease 1 29.5 INS GAST CCK ALB
46 gastroesophageal reflux 29.5 NPY MLN GAST CCK
47 pheochromocytoma 29.5 NTRK1 NPY NGF MLN EPO
48 peripheral nervous system disease 29.4 TTR SPTLC1 SCN9A SCN11A NTRK1 NGF
49 diabetes mellitus, noninsulin-dependent 29.1 TTR NPY NGF INS CCK ALB
50 body mass index quantitative trait locus 11 28.9 NPY MLN INS CCK ALB AKR1B1

Graphical network of the top 20 diseases related to Autonomic Neuropathy:



Diseases related to Autonomic Neuropathy

Symptoms & Phenotypes for Autonomic Neuropathy

MGI Mouse Phenotypes related to Autonomic Neuropathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 AKR1B1 ALB CCK ELP1 EPO GAST
2 behavior/neurological MP:0005386 10.11 AKR1B1 ELP1 INS KIF1A NGF NPY
3 mortality/aging MP:0010768 9.97 AKR1B1 ALB ELP1 EPO GAST INS
4 integument MP:0010771 9.96 ELP1 EPO INS KIF1A NGF NTRK1
5 nervous system MP:0003631 9.73 CCK ELP1 INS KIF1A NGF NPY
6 renal/urinary system MP:0005367 9.28 AKR1B1 ALB CCK ELP1 INS NPY

Drugs & Therapeutics for Autonomic Neuropathy

Drugs for Autonomic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
2
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
3
Methyltestosterone Approved Phase 4 58-18-4 6010
4
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
5
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
6
Testosterone enanthate Approved Phase 4 315-37-7 9416
7
Lenograstim Approved, Investigational Phase 4 135968-09-1
8
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
9
Glimepiride Approved Phase 4 93479-97-1 3476
10
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
11
Metformin Approved Phase 4 657-24-9 14219 4091
12
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
13
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
14
Norepinephrine Approved Phase 4 51-41-2 439260
15
Donepezil Approved Phase 4 120014-06-4 3152
16
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
17
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
18 Benphothiamine Phase 4
19
protease inhibitors Phase 4
20 HIV Protease Inhibitors Phase 4
21 Alpha-lipoic Acid Phase 4
22 Thioctic Acid Phase 4
23 Dipeptidyl-Peptidase IV Inhibitors Phase 4
24 Calcium, Dietary Phase 4
25 Anabolic Agents Phase 4
26 Testosterone 17 beta-cypionate Phase 4
27 Antineoplastic Agents, Hormonal Phase 4
28 Androgens Phase 4
29 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
30 Antiparkinson Agents Phase 4
31 Immunologic Factors Phase 4
32 Adjuvants, Immunologic Phase 4
33 Vasodilator Agents Phase 4
34 Dopamine agonists Phase 4
35 Rosuvastatin Calcium Phase 4 147098-20-2
36 Immunosuppressive Agents Phase 4
37 Anti-Arrhythmia Agents Phase 4
38 Liver Extracts Phase 4
39 Phosphodiesterase Inhibitors Phase 4
40 Phosphodiesterase 5 Inhibitors Phase 4
41 Antihypertensive Agents Phase 4
42 Angiotensin-Converting Enzyme Inhibitors Phase 4
43 Sodium-Glucose Transporter 2 Inhibitors Phase 4
44 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)... Phase 4
45 Natriuretic Agents Phase 4
46 Angiotensin Receptor Antagonists Phase 4
47 Sodium Chloride Symporter Inhibitors Phase 4
48 diuretics Phase 4
49 Central Nervous System Depressants Phase 4
50 Cholinergic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 128)
# Name Status NCT ID Phase Drugs
1 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
2 Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
3 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
4 The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy by Comparing the Change of HRV Index & ANS Function:A 6month Multicenter, Randomized, Open Label Clinical Trial CANON Study Completed NCT02056366 Phase 4 α-lipoic acid
5 Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor on Ischemic Burden in Stable Ischemic Heart Disease Patients Completed NCT03178591 Phase 4 vildagliptin;Dapagliflozin
6 Bone Marrow Responsiveness to Pharmacologic Mobilization of Progenitor Cells in Diabetic Versus Non-diabetic Patients Completed NCT01102699 Phase 4 Filgrastim, hrG-CSF
7 Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
8 Statin Therapy is Associated With Low Testosterone and Sexual Function in Men With Type 2 Diabetes Completed NCT02612714 Phase 4 Rosuvastatin
9 Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D) Completed NCT02973477 Phase 4 Dapagliflozin;Glimepiride
10 Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A Completed NCT01803828 Phase 4 Tadalafil;Placebo
11 RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
12 A Double-blind, Randomized, Parallel 2- Arm Study to Compare the Efficacy of Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes Who Are Receiving Background Standard-of-care Cardio-metabolic Therapy With Metformin, an Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker, and a Statin. Not yet recruiting NCT03640221 Phase 4 Ertugliflozin;Hydrochlorothiazide 12.5mg
13 Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy Terminated NCT00619983 Phase 4 donepezil;duloxetine;donepezil 2.5 mg and duloxetine 30mg;placebo;gabapentin
14 Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance Withdrawn NCT00306826 Phase 4 pioglitazone;simvastatin;pioglitazone + simvastatin
15 A 16-week, Randomised, Double-blind, Placebo-controlled, Single-centre Study to Investigate Fluid Retention in Insulin-treated Subjects With Type 2 Diabetes Mellitus and Varying Degrees of Autonomic Neuropathy When Administered Rosiglitazone 4mg Twice Daily Completed NCT00422955 Phase 3 rosiglitazone
16 Oxidative Stress and Cardiovascular Denervation in Diabetes: An Interventional Trial Completed NCT00116207 Phase 3 ORAL ANTIOXIDANT
17 Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT) Completed NCT00594152 Phase 3 CIIIT
18 A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy. Completed NCT01522235 Phase 2, Phase 3 Double blinded IVIg
19 The Effect of Diflunisal on Familial Amyloidosis Completed NCT00294671 Phase 2, Phase 3 diflunisal
20 Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia Completed NCT01212484 Phase 3 Carbidopa;Placebo
21 A Multi-center, Open-label Study to Assess the Long-term Safety of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension Completed NCT01132326 Phase 3 Droxidopa
22 Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients Recruiting NCT03593304 Phase 2, Phase 3 Injection Mecobalamin;Tablet Pyridoxine hydrochlorid;Normal saline;Oral Placebo
23 Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy-TINSAL -T1DN Recruiting NCT02936843 Phase 2, Phase 3 Salsalate;PLACEBO
24 A Phase II, Open-label, Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis Unknown status NCT01730716 Phase 2
25 Effect of a DPP-IV Inhibitor Treatment on the Secretion of Glucagon in Patients Presenting With Type 1 Diabetes Mellitus With or Without Autonomic Neuropathy Completed NCT01452113 Phase 2 Vildagliptin
26 A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-639 to Placebo in Subjects With Diabetic Neuropathic Pain Completed NCT01345045 Phase 2 ABT-639;pregabalin;Placebo
27 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of L-Serine in Subjects With Hereditary Sensory Neuropathy Type 1 Completed NCT01733407 Phase 1, Phase 2 L-serine;placebo
28 Chronic Diabetic Painful Neuropathy and Cardiovascular Risk Factors in NIDDM: An Alternative Approach. Completed NCT00010751 Phase 2
29 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy Completed NCT00760955 Phase 2 TAK-583;TAK-583;TAK-583;Placebo
30 Carbidopa in Familial Dysautonomia: Phase-II Study, Investigational New Drug (IND) 117435, Date: 01/07/13 Completed NCT02553265 Phase 2 Carbidopa Low Dose;Carbidopa High Dose
31 Improving Diabetic Foot Ulcers With Atorvastatin Completed NCT00134550 Phase 2 Atorvastatin (10 mg or 80 mg)
32 A Double-Blind, Randomized, Placebo-Controlled Trial To Evaluate The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes Recruiting NCT02915263 Phase 2 IGIV-C;0.9% Sodium Chloride
33 Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes Recruiting NCT03085771 Phase 2 desferal;Isotonic saline
34 Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Not yet recruiting NCT03446807 Phase 2 Droxidopa;Placebo Oral Tablet
35 The Safety , Tolerability and Efficacy of Dronabinol, a Synthetic Endocannabinoid Receptor Agonist, for the Treatment of Nausea and Vomiting in Patients With Familial Dysautonomia Withdrawn NCT02608931 Phase 2 Dronabinol
36 Cardiac Autonomic Neuropathy in Patients With Metabolic Syndrome Completed NCT00907127 Phase 1
37 The Safety and Tolerability of Kinetin, a Nutritional Supplement That Corrects the Splicing Defect, in Patients With Familial Dysautonomia Completed NCT02274051 Phase 1
38 A Dose Response Trial of Droxidopa to Treat Hypotension in Persons With SCI Completed NCT01354158 Phase 1 Droxidopa
39 Phase I Dose Escalation Study of N-acetylcysteine (NAC) Administered Intravenously (IV) in Conjunction With Intraperitoneal (IP) Administered Cisplatin and IV/IP Paclitaxel in Patients With Stage III or IV Ovarian Cancer Withdrawn NCT01138137 Phase 1 Paclitaxel;N-acetylcysteine;Cisplatin
40 A Comparison Between Pupillometry, Heart Rate Variability and Metaiodobenzylguanidine Scintigraphy for the Diagnosis of Early Diabetic Autonomic Neuropathy in Type 1 Diabetes Unknown status NCT01822431
41 The Relationship Between Vascular Adhesion Protein-1 and Diabetic Cardiovascular Autonomic Neuropathy Unknown status NCT01706289
42 Silent Myocardial Ischemia in Patients With Diabetes Type 2: Diagnostic Value of Myocardial Strains Left Ventricular Resting Echocardiography 2D and 3D, Compared to Stress Echocardiography Unknown status NCT02885428
43 Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus Unknown status NCT01545024 Sitagliptin, 50 mg once per day per os
44 ECG Changes in Children and Adolescents With Type 1 Diabetes Unknown status NCT03260998
45 Autonomic Cardiovascular Neuropathy in Recently Diagnosed DM2 Patients and in Pre-Diabetes Patients Unknown status NCT02931773
46 Safety and Efficacy of Single Ankle, Single Popliteal or Combined Ankle and Popliteal Block for Diabetic Foot Surgery: A Comparative Study Unknown status NCT03155568 Bupivacaine
47 Gastrointestinal Motility Among Diabetes Patients Unknown status NCT02573519 3D-Transit during treatment with Pyridostigmine
48 Acute Effects of Low-level Laser Therapy in Functional Capacity of Patients With Chronic Kidney Disease: Randomized Clinical Trial Unknown status NCT02944760
49 Effects of High-intensity Inspiratory Muscle Training in Chronic Kidney Disease: Randomized Clinical Trial Unknown status NCT03082404
50 Effects of Neuromuscular Electrical Stimulation on Glucose Levels and Glucose Variability in Patients With Type 2 Diabetes: a Randomized Clinical Trial Unknown status NCT03256747

Search NIH Clinical Center for Autonomic Neuropathy

Genetic Tests for Autonomic Neuropathy

Anatomical Context for Autonomic Neuropathy

MalaCards organs/tissues related to Autonomic Neuropathy:

40
Heart, Testes, Kidney, Liver, Skin, Brain, Spinal Cord

Publications for Autonomic Neuropathy

Articles related to Autonomic Neuropathy:

(show top 50) (show all 4320)
# Title Authors PMID Year
1
Perspectives of nuclear diagnostic imaging in diabetic cardiomyopathy. 54 61
19939648 2010
2
Erythropoietin response to anemia and its association with autonomic neuropathy in type 2 diabetic patients without advanced renal failure. 54 61
19303331 2010
3
In vitro receptor binding properties of a "painless" NGF mutein, linked to hereditary sensory autonomic neuropathy type V. 54 61
19945432 2010
4
Small bowel bacterial overgrowth and type 1 diabetes. 54 61
20085122 2009
5
Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. 54 61
19493541 2009
6
Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). 54 61
19470886 2009
7
A novel NGFB point mutation: a phenotype study of heterozygous patients. 54 61
18420729 2009
8
Loss of mouse Ikbkap, a subunit of elongator, leads to transcriptional deficits and embryonic lethality that can be rescued by human IKBKAP. 54 61
19015235 2009
9
Gastroparesis is associated with oxytocin deficiency, oesophageal dysmotility with hyperCCKemia, and autonomic neuropathy with hypergastrinemia. 54 61
19243587 2009
10
Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells. 54 61
19065606 2009
11
Specific pathogen free conditions prevent transthyretin amyloidosis in mouse models. 54 61
18357510 2008
12
Plantar fascia thickness, a measure of tissue glycation, predicts the development of complications in adolescents with type 1 diabetes. 54 61
18332152 2008
13
The pathophysiology and diagnosis of orthostatic hypotension. 54 61
18368300 2008
14
Potential roles of erythropoietin in the management of anaemia and other complications diabetes. 54 61
17645562 2008
15
Aldose reductase, still a compelling target for diabetic neuropathy. 54 61
18220710 2008
16
A humanized IKBKAP transgenic mouse models a tissue-specific human splicing defect. 54 61
17644305 2007
17
In vivo stabilization of mutant human transthyretin in transgenic mice. 54 61
17701470 2007
18
Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes. 54 61
17609399 2007
19
[The diagnosis and management of familial amyloid polyneuropathy]. 54 61
17086153 2006
20
Management strategies for brittle diabetes. 54 61
17072232 2006
21
Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. 54 61
16862048 2006
22
Performing only one cardiovascular reflex test has a high positive predictive value for diagnosing autonomic neuropathy in patients with chronic renal failure on hemodialysis. 54 61
16825086 2006
23
Nerve growth factor-tyrosine kinase A pathway is involved in thermoregulation and adaptation to stress: studies on patients with hereditary sensory and autonomic neuropathy type IV. 54 61
15695606 2005
24
Familial insensitivity to pain (HSAN V) and a mutation in the NGFB gene. A neurophysiological and pathological study. 54 61
15468048 2004
25
Heart failure in diabetes mellitus: causal and treatment considerations. 54 61
15729210 2004
26
Kidney and anemia in familial amyloidosis type I. 54 61
15496172 2004
27
A case of insulin edema with inappropriate hyperaldosteronism. 54 61
15762045 2004
28
Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric Type 2 diabetic patients? 54 61
15498082 2004
29
The evaluation of autonomic nervous function in a patient with hereditary sensory and autonomic neuropathy type IV with novel mutations of the TRKA gene. 54 61
15534759 2004
30
Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. 54 61
15294881 2004
31
The anaesthetic management of patients with congenital insensitivity to pain with anhidrosis. 54 61
15078381 2004
32
Anaemia in diabetes. 54 61
15103543 2004
33
Severe and disabling diabetic autonomic neuropathy: a case report. 54 61
15120708 2004
34
Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. 54 61
14747240 2004
35
Erythropoietin treatment in the neuropsychiatric porphyrias. 54 61
14637267 2003
36
Nerve growth factor and diabetic neuropathy. 54 61
14668049 2003
37
Gallbladder motility in obesity, diabetes mellitus and coeliac disease. 54 61
12974503 2003
38
Insulin resistant state in type 2 diabetes is related to advanced autonomic neuropathy. 54 61
12716078 2003
39
Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. 54 61
12706936 2003
40
Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia. 54 61
12577200 2003
41
[Erythropoietin administration in diabetic patients]. 54 61
14974347 2003
42
Diabetes mellitus and heart failure. 54 61
15815121 2003
43
A new transthyretin variant Leu55Gln in a patient with systemic amyloidosis. 54 61
12557757 2002
44
No mutation in the TRKA (NTRK1) gene encoding a receptor tyrosine kinase for nerve growth factor in a patient with hereditary sensory and autonomic neuropathy type V. 54 61
12210794 2002
45
Autonomic neuropathy is associated with impaired pancreatic polypeptide and neuropeptide Y responses to insulin-induced hypoglycaemia in Type I diabetic patients. 54 61
12187924 2002
46
Observations on haematological and cardiovascular effects of erythropoietin treatment in multiple system atrophy with sympathetic failure. 54 61
12269555 2002
47
Prevalence of Q-T interval dispersion in type 1 diabetes and its relation with cardiac ischemia : the EURODIAB IDDM Complications Study Group. 54 61
11919128 2002
48
Neuroadrenergic denervation of the lung in type I diabetes mellitus complicated by autonomic neuropathy. 54 61
11834655 2002
49
Changes of gastric emptying rate and gastrin levels are early indicators of autonomic neuropathy in type II diabetic patients. 54 61
11710799 2001
50
Erythropoietin treatment of postural hypotension in anemic type 1 diabetic patients with autonomic neuropathy: a case study of four patients. 54 61
11375382 2001

Variations for Autonomic Neuropathy

Expression for Autonomic Neuropathy

Search GEO for disease gene expression data for Autonomic Neuropathy.

Pathways for Autonomic Neuropathy

Pathways related to Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.56 SCN9A SCN11A NTRK1 NPY NGF
2 10.78 TTR INS ALB
3
Show member pathways
10.3 NTRK1 NGF
4 10 GAST CCK

GO Terms for Autonomic Neuropathy

Cellular components related to Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 TTR NPY NGF MLN INS GAST
2 extracellular space GO:0005615 9.61 TTR NPY NGF INS GAST EPO
3 axon GO:0030424 9.17 SCN9A SCN11A NTRK1 NGF KIF1A DST
4 serine C-palmitoyltransferase complex GO:0017059 9.16 SPTLC2 SPTLC1

Biological processes related to Autonomic Neuropathy according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 NTRK1 NGF EPO ALB AKR1B1
2 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.61 NTRK1 INS EPO
3 sensory perception of pain GO:0019233 9.54 SCN9A RETREG1 NTRK1
4 membrane depolarization during action potential GO:0086010 9.49 SCN9A SCN11A
5 nerve growth factor signaling pathway GO:0038180 9.46 NTRK1 NGF
6 sphingosine biosynthetic process GO:0046512 9.4 SPTLC2 SPTLC1
7 sphingomyelin biosynthetic process GO:0006686 9.32 SPTLC2 SPTLC1
8 positive regulation of lipophagy GO:1904504 9.26 SPTLC2 SPTLC1
9 negative regulation of protein oligomerization GO:0032460 9.16 INS ALB
10 positive regulation of Ras protein signal transduction GO:0046579 9.13 NTRK1 NGF EPO
11 sphinganine biosynthetic process GO:0046511 8.62 SPTLC2 SPTLC1

Molecular functions related to Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pyridoxal phosphate binding GO:0030170 9.33 SPTLC2 SPTLC1 ALB
2 hormone activity GO:0005179 9.17 TTR NPY MLN INS GAST EPO
3 serine C-palmitoyltransferase activity GO:0004758 8.96 SPTLC2 SPTLC1

Sources for Autonomic Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....